DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Diroximel fumarate
Diroximel fumarate
211855Orig1s000
Oral MS Disease-Modifying Therapies C21142-A
Multiple Sclerosis
Prior Authorization Multiple Sclerosis – Ponvory™ (Ponesimod Tablets)
5948 6 March 2020 Freedom of Information Request I Am Writing In
Timeline of Progress in MS Research
Ponesimod (Ponvory) Reference Number: ERX.SPA.437 Effective Date: 06.01.21 Last Review Date: 05.21 Line of Business: Commercial, Medicaid Revision Log
Multiple Sclerosis Disease Modifying Therapy
Glatopa™ (Glatiramer Acetate)
Prior Authorization Multiple Sclerosis – Aubagio® (Teriflunomide Tablets)
211855Orig1s000
Gudesblatt M,1 Wray S,2 Miller C,3 Hanna J,4 Lopez-Bresnahan M,5
Ponvory (Ponesimod) Annual Review Date: 05/20/2021
Utah Medicaid Pharmacy and Therapeutics Committee Drug
Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
FULL SCIENTIFIC PROGRAM Full Scientific Program As of September 12, 2020
RESEARCH MS UPDATE Written and Compiled by Tom Garry and Pete Kelly
Multiple Sclerosis NOTICE
Top View
Biogen MS & R&D Webcast Presentation
Center Without Walls Program UCLA Joins Our Stellar Team of MS Centers
VUMERITY™ Safely and Effectively
Complementary and Alternative Therapies
5.01.565 Pharmacotherapy of Multiple Sclerosis
Multiple Sclerosis
Clinical Policy: Dimethyl Fumarate (Tecfidera), Diroximel Fumarate
Multiple Sclerosis Agents
Diroximel Fumarate for Relapsing-Remitting Multiple Sclerosis
Ofatumumab Ponesimod Brand Name (Manufacturer): Kesimpta (Novartis) Ponvory (Janssen) Dossier Received: Yes, for Ofatumumab
Multiple Sclerosis Agents Prior Authorization with Quantity Limit - Through Preferred Agent Program Summary
Diroximel Fumarate (Vumerity) Reference Number: CP.PHAR.249 Effective Date: 09.01.16 Last Review Date: 08.20 Line of Business: Medicaid Revision Log
MS Research Update
Dimethyl Fumarate and Its Esters: a Drug with Broad Clinical Utility?
Multiple Sclerosis Therapy – Oral and Subcutaneous
Multiple Sclerosis EOCCO POLICY
Multiple Sclerosis – Unified Formulary
Multiple Sclerosis Agents Pa Summary
Prior Authorization Multiple Sclerosis and Ulcerative Colitis – Zeposia® (Ozanimod Capsules)
Ponesimod (Ponvory™) New Drug Update
Diroximel Fumarate
Multiple Sclerosis Agents
Relapsing Remitting Multiple Sclerosis: Treatment Update Outline
Multiple Sclerosis Agents Aubagio® (Teriflunomide) Bafiertam
CP.PHAR.249 Dimethyl Fumarate (Tecfidera), Diroximel
And Monomethyl Fumarate (Bafiertam™)
GILENYA (Fingolimod) MAVENCLAD (Cladrabine) MAYZENT (Siponimod) PONVORY (Ponesimod) TECFIDERA (Dimethyl Fumarate) VUMERITY (Diroximel Fumarate) ZEPOSIA (Ozanimod)
Multiple Sclerosis Agents
Cladribine (Mavenclad) Reference Number: CP.PHAR.422 Effective Date: 09.01.19 Last Review Date: 08.20 Line of Business: Commercial, HIM, Medicaid Revision Log